CN103540612A - Slow virus recombinant plasmid for inhibiting epithelial-mesenchymal transition of breast tumor - Google Patents

Slow virus recombinant plasmid for inhibiting epithelial-mesenchymal transition of breast tumor Download PDF

Info

Publication number
CN103540612A
CN103540612A CN201310494959.0A CN201310494959A CN103540612A CN 103540612 A CN103540612 A CN 103540612A CN 201310494959 A CN201310494959 A CN 201310494959A CN 103540612 A CN103540612 A CN 103540612A
Authority
CN
China
Prior art keywords
csd
slow virus
cav
recombinant plasmid
district
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201310494959.0A
Other languages
Chinese (zh)
Other versions
CN103540612B (en
Inventor
孙巍
遇红梅
房明丽
王丽颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin University
Original Assignee
Jilin University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilin University filed Critical Jilin University
Priority to CN201310494959.0A priority Critical patent/CN103540612B/en
Publication of CN103540612A publication Critical patent/CN103540612A/en
Application granted granted Critical
Publication of CN103540612B publication Critical patent/CN103540612B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a slow virus recombinant plasmid for inhibiting epithelial-mesenchymal transition of breast tumor, belonging to the field of biotechnology. The nucleotide sequence of the slow virus recombinant plasmid is as shown in SEQ ID NO: 1. Through the local injection of the recombinant plasmid for treating breast carcinoma, the activity of tumor-associated protein in the matrix beside the tumor carcinoma can be obviously inhibited. The epithelial-mesenchymal transition can be obviously inhibited through local injection of the FuGW-CSD recombinant plasmid for treating the breast carcinoma, and the transfer of the breast carcinoma is inhibited.

Description

A kind of slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal
Technical field
The invention belongs to biological technical field, be specially a kind of recombinant plasmid, by expressing object peptide section, interact with tumor metastasis related protein, reach the inhibition object that breast tumor Epithelial and stromal is transformed.
Background technology
Epithelial and stromal transforms (Epithelial-mesenchymal transition, EMT), being that epithelial cell is converted into the cell with interstitial phenotype by specific program, is the core link of the malignant cell acquisition migration and invasion ability in epithelial cell source.
Matrix metalloproteinase (MMP) and transforming growth factor TGF-β are the key protein matter of current known participation EMT.MMP is the ability with degradation of cell epimatrix composition, is the enzyme of current known unique energy degrade collagen fiber, and its activity has certain effect to the inactivation of cell adhesion system.It plays a role in vascularization and metastases at tumor growth; TGF-β mainly promotes the generation of EMT by each integrin signaling pathway, promote the cell transcription process that Smad3 molecule relies on, the signal transduction pathway of the P38MAP kinase pathways that also can rely on by non-Smad molecule and the mediation of GTP enzyme promotes that EMT develops, in the invasion and attack and transfer process of tumour, TGF-β impels cell-cycle arrest, accelerate apoptosis, can also induce the EMT state that maintains.
Cav-1 is combined with TGF-β I kinase activation district by scaffolding district (CSD district), suppresses phosphorylation and downstream activity thereof that TGF regulates Smad-2, plays the effect of kinase inhibitor; CAV gene level is eliminated the expression and secretion of MMP2 and 9, and CAV crosses the secretion of expressing the remarkable MMP of reduction.
Summary of the invention
The invention provides a kind of recombinant plasmid that suppresses breast tumor transfer that is used for the treatment of.
The technical scheme that the present invention takes is: a kind of slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal, its nucleotide sequence is as described in SEQ ID NO:1.
The slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal of the present invention, the series connection of caveolin scaffolding district CAV-1 CSD expressed sequence repeats 3 times, this caveolin scaffolding district CAV-1 CSD coding nucleotide sequence as described in SEQ ID NO:3, aminoacid sequence is as described in SEQ ID NO:5, in FuGW slow virus plasmid, under ubiquitination promotor, by BamH I, be connected with Bgl II restriction enzyme site.
The slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal of the present invention, CAV-1 CSD coding nucleotide sequence in caveolin scaffolding district is as described in SEQ ID NO:2.
The slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal of the present invention, CAV-1 CSD encoding amino acid sequence in caveolin scaffolding district is as described in SEQ ID NO:4.
Of the present invention as follows for suppressing the construction process of the slow virus recombinant plasmid that breast tumor Epithelial and stromal transforms:
(1) design of the Express Sequence Tags of caveolin scaffolding district CAV-1 CSD: from the expressed sequence in NCBI acquisition CAV-1 CSD district, by this section of sequence series connection in triplicate, at two ends, introduce BamH I and Bgl II isocaudarner restriction enzyme site, according to this section of sequences Design, be used for overlapping the primer of PCR:
primer1-5’:
CAAATATTGGTTTTATCGCGATGGCATTTGGAAAGCGAGCTTTACCACCTTTACCGTGACCAAATATTG;
primer1-3’:
GTCACGGTAAAGGTGGTAAAGCTCGCTTTCCAAATGCCATCGCGATAAAACCAATATTTGGTCACGGTA;
primer2-5’:
GGATCCCGCAGCGATGGCATTTGGAAAGCGAGCTTTACCACCTTTACCGTGACCAAATATTGGTTTTATCG;
primer2-3’: AGATCTGCTGCCGCGATAAAACCAATATTTGGTCACGGTAAAGGTGGTA;
(2) acquisition of the Express Sequence Tags of caveolin scaffolding district CAV-1 CSD: the sequence that obtains tri-series connection of CAV-1 CSD by the method for overlap joint PCR, PCR process is used TaqDNA polysaccharase, single base A is contained at these PCR product two ends, it is connected under the effect of T4 ligase enzyme in T carrier, obtain the T vector plasmid that contains tri-series connection of CAV-1 CSD;
(3) structure of recombinant plasmid FuGW-CSD: the T vector plasmid that step (two) is obtained carries out BamH I and Bgl II double digestion, BamH I and Bgl II are isocaudarners, FUGW slow virus plasmid is carried out to BamH I single endonuclease digestion, and PCR product is cloned under FUGW slow virus plasmid ubiquitination promotor by BamH I restriction enzyme site.
Beneficial effect of the present invention: by the repetition of connecting of CAV-1 CSD region sequence, the method by subclone enters slow virus plasmid, is configured to a recombinant expression plasmid FuGW-CSD; This recombinant plasmid local injection mammary cancer can obviously suppress the activity of tumor correlated albumen in the other matrix of tumour cancer.FuGW-CSD recombinant plasmid local injection mammary cancer can obviously suppress its Epithelial and stromal and transform, and suppresses its transfer.Fill up the blank that does not have at present local injection to suppress the recombinant plasmid of breast tumor transfer, development.
Accompanying drawing explanation
Fig. 1 is the FuGW-CSD plasmid map of invention;
Fig. 2 is the spirogram that contains that FuGW-CSD plasmid reduces EMT marker protein;
Fig. 3 is that FuGW-CSD plasmid suppresses tumor growth and transferring picture.
Embodiment
Suppress the slow virus recombinant plasmid that breast tumor Epithelial and stromal transforms, its nucleotide sequence is as described in SEQ ID NO:1.
The slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal of the present invention, the series connection of caveolin scaffolding district CAV-1 CSD expressed sequence repeats 3 times, this caveolin scaffolding district CAV-1 CSD coding nucleotide sequence as described in SEQ ID NO:3, aminoacid sequence is as described in SEQ ID NO:5, in FuGW slow virus plasmid, under ubiquitination promotor, by BamH I, be connected with Bgl II restriction enzyme site.
The slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal of the present invention, CAV-1 CSD coding nucleotide sequence in caveolin scaffolding district is as described in SEQ ID NO:2.
The slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal of the present invention, CAV-1 CSD encoding amino acid sequence in caveolin scaffolding district is as described in SEQ ID NO:4.
Of the present invention as follows for suppressing the construction process of the slow virus recombinant plasmid that breast tumor Epithelial and stromal transforms:
(1) design of the Express Sequence Tags of caveolin scaffolding district CAV-1 CSD: from the expressed sequence in NCBI acquisition CAV-1 CSD district, by this section of sequence series connection in triplicate, at two ends, introduce BamH I and Bgl II isocaudarner restriction enzyme site, according to this section of sequences Design, be used for overlapping the primer of PCR:
primer1-5’:
CAAATATTGGTTTTATCGCGATGGCATTTGGAAAGCGAGCTTTACCACCTTTACCGTGACCAAATATTG;
primer1-3’:
GTCACGGTAAAGGTGGTAAAGCTCGCTTTCCAAATGCCATCGCGATAAAACCAATATTTGGTCACGGTA;
primer2-5’:
GGATCCCGCAGCGATGGCATTTGGAAAGCGAGCTTTACCACCTTTACCGTGACCAAATATTGGTTTTATCG;
primer2-3’: AGATCTGCTGCCGCGATAAAACCAATATTTGGTCACGGTAAAGGTGGTA;
(2) acquisition of the Express Sequence Tags of caveolin scaffolding district CAV-1 CSD: the sequence that obtains tri-series connection of CAV-1 CSD by the method for overlap joint PCR, PCR process is used TaqDNA polysaccharase, single base A is contained at these PCR product two ends, it is connected under the effect of T4 ligase enzyme in T carrier, obtain the T vector plasmid that contains tri-series connection of CAV-1 CSD;
(3) structure of recombinant plasmid FuGW-CSD: the T vector plasmid that step (two) is obtained carries out BamH I and Bgl II double digestion, BamH I and Bgl II are isocaudarners, FUGW slow virus plasmid is carried out to BamH I single endonuclease digestion, and PCR product is cloned under FUGW slow virus plasmid ubiquitination promotor by BamH I restriction enzyme site.
Test example 1, FuGW-CSD plasmid reduces the content of EMT marker protein
Set up mouse tumor animal model, after tumor growth, tumour is taken out in Mice Body, in tumour surrounding tissue, inject FuGW-CSD, set up injecting normal saline group simultaneously.Get cancer beside organism and detect EMT mark MMP and the variation of TGF-β protein expression.Find that these two kinds of protein contents of tumor group are all higher than Normal group, in FuGW-CSD treatment group, MMP, TGF-β protein content comparison of tumor group significantly reduce, and see Fig. 1.
Test example 2, FuGW-CSD plasmid suppresses tumor growth and transfer
Set up mouse tumor animal model, after tumor growth, in tumour surrounding tissue, inject FuGW-CSD, observe tumor growth situation.Find that tumor group has other position metastatic tumour lumps, and FuGW-CSD treatment group mouse does not have metastases sign except other positions, tumour affected part, and gross tumor volume has and obviously dwindle, see Fig. 2.
SEQUENCE LISTING
<110> Jilin University
<120> slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal
<130> jlusw2013-1
<160> 5
<170> PatentIn version 3.3
<210> 1
<211> 9939
<212> DNA
<213> synthetic
<400> 1
gtcgacggat cgggagatct cccgatcccc tatggtgcac tctcagtaca atctgctctg 60
atgccgcata gttaagccag tatctgctcc ctgcttgtgt gttggaggtc gctgagtagt 120
gcgcgagcaa aatttaagct acaacaaggc aaggcttgac cgacaattgc atgaagaatc 180
tgcttagggt taggcgtttt gcgctgcttc gcgatgtacg ggccagatat acgcgttgac 240
attgattatt gactagttat taatagtaat caattacggg gtcattagtt catagcccat 300
atatggagtt ccgcgttaca taacttacgg taaatggccc gcctggctga ccgcccaacg 360
acccccgccc attgacgtca ataatgacgt atgttcccat agtaacgcca atagggactt 420
tccattgacg tcaatgggtg gagtatttac ggtaaactgc ccacttggca gtacatcaag 480
tgtatcatat gccaagtacg ccccctattg acgtcaatga cggtaaatgg cccgcctggc 540
attatgccca gtacatgacc ttatgggact ttcctacttg gcagtacatc tacgtattag 600
tcatcgctat taccatggtg atgcggtttt ggcagtacat caatgggcgt ggatagcggt 660
ttgactcacg gggatttcca agtctccacc ccattgacgt caatgggagt ttgttttggc 720
accaaaatca acgggacttt ccaaaatgtc gtaacaactc cgccccattg acgcaaatgg 780
gcggtaggcg tgtacggtgg gaggtctata taagcagcgc gttttgcctg tactgggtct 840
ctctggttag accagatctg agcctgggag ctctctggct aactagggaa cccactgctt 900
aagcctcaat aaagcttgcc ttgagtgctt caagtagtgt gtgcccgtct gttgtgtgac 960
tctggtaact agagatccct cagacccttt tagtcagtgt ggaaaatctc tagcagtggc 1020
gcccgaacag ggacttgaaa gcgaaaggga aaccagagga gctctctcga cgcaggactc 1080
ggcttgctga agcgcgcacg gcaagaggcg aggggcggcg actggtgagt acgccaaaaa 1140
ttttgactag cggaggctag aaggagagag atgggtgcga gagcgtcagt attaagcggg 1200
ggagaattag atcgcgatgg gaaaaaattc ggttaaggcc agggggaaag aaaaaatata 1260
aattaaaaca tatagtatgg gcaagcaggg agctagaacg attcgcagtt aatcctggcc 1320
tgttagaaac atcagaaggc tgtagacaaa tactgggaca gctacaacca tcccttcaga 1380
caggatcaga agaacttaga tcattatata atacagtagc aaccctctat tgtgtgcatc 1440
aaaggataga gataaaagac accaaggaag ctttagacaa gatagaggaa gagcaaaaca 1500
aaagtaagac caccgcacag caagcggccg ctgatcttca gacctggagg aggagatatg 1560
agggacaatt ggagaagtga attatataaa tataaagtag taaaaattga accattagga 1620
gtagcaccca ccaaggcaaa gagaagagtg gtgcagagag aaaaaagagc agtgggaata 1680
ggagctttgt tccttgggtt cttgggagca gcaggaagca ctatgggcgc agcgtcaatg 1740
acgctgacgg tacaggccag acaattattg tctggtatag tgcagcagca gaacaatttg 1800
ctgagggcta ttgaggcgca acagcatctg ttgcaactca cagtctgggg catcaagcag 1860
ctccaggcaa gaatcctggc tgtggaaaga tacctaaagg atcaacagct cctggggatt 1920
tggggttgct ctggaaaact catttgcacc actgctgtgc cttggaatgc tagttggagt 1980
aataaatctc tggaacagat ttggaatcac acgacctgga tggagtggga cagagaaatt 2040
aacaattaca caagcttaat acactcctta attgaagaat cgcaaaacca gcaagaaaag 2100
aatgaacaag aattattgga attagataaa tgggcaagtt tgtggaattg gtttaacata 2160
acaaattggc tgtggtatat aaaattattc ataatgatag taggaggctt ggtaggttta 2220
agaatagttt ttgctgtact ttctatagtg aatagagtta ggcagggata ttcaccatta 2280
tcgtttcaga cccacctccc aaccccgagg ggacccgaca ggcccgaagg aatagaagaa 2340
gaaggtggag agagagacag agacagatcc attcgattag tgaacggatc ggcactgcgt 2400
gcgccaattc tgcagacaaa tggcagtatt catccacaat tttaaaagaa aaggggggat 2460
tggggggtac agtgcagggg aaagaatagt agacataata gcaacagaca tacaaactaa 2520
agaattacaa aaacaaatta caaaaattca aaattttcgg gtttattaca gggacagcag 2580
agatccagtt tggttaatta agggtgcagc ggcctccgcg ccgggttttg gcgcctcccg 2640
cgggcgcccc cctcctcacg gcgagcgctg ccacgtcaga cgaagggcgc aggagcgttc 2700
ctgatccttc cgcccggacg ctcaggacag cggcccgctg ctcataagac tcggccttag 2760
aaccccagta tcagcagaag gacattttag gacgggactt gggtgactct agggcactgg 2820
ttttctttcc agagagcgga acaggcgagg aaaagtagtc ccttctcggc gattctgcgg 2880
agggatctcc gtggggcggt gaacgccgat gattatataa ggacgcgccg ggtgtggcac 2940
agctagttcc gtcgcagccg ggatttgggt cgcggttctt gtttgtggat cgctgtgatc 3000
gtcacttggt gagttgcggg ctgctgggct ggccggggct ttcgtggccg ccgggccgct 3060
cggtgggacg gaagcgtgtg gagagaccgc caagggctgt agtctgggtc cgcgagcaag 3120
gttgccctga actgggggtt ggggggagcg cacaaaatgg cggctgttcc cgagtcttga 3180
atggaagacg cttgtaaggc gggctgtgag gtcgttgaaa caaggtgggg ggcatggtgg 3240
gcggcaagaa cccaaggtct tgaggccttc gctaatgcgg gaaagctctt attcgggtga 3300
gatgggctgg ggcaccatct ggggaccctg acgtgaagtt tgtcactgac tggagaactc 3360
gggtttgtcg tctggttgcg ggggcggcag ttatgcggtg ccgttgggca gtgcacccgt 3420
acctttggga gcgcgcgcct cgtcgtgtcg tgacgtcacc cgttctgttg gcttataatg 3480
cagggtgggg ccacctgccg gtaggtgtgc ggtaggcttt tctccgtcgc aggacgcagg 3540
gttcgggcct agggtaggct ctcctgaatc gacaggcgcc ggacctctgg tgaggggagg 3600
gataagtgag gcgtcagttt ctttggtcgg ttttatgtac ctatcttctt aagtagctga 3660
agctccggtt ttgaactatg cgctcggggt tggcgagtgt gttttgtgaa gttttttagg 3720
caccttttga aatgtaatca tttgggtcaa tatgtaattt tcagtgttag actagtaaag 3780
cttctgcagg tcgactctag aaaattgtcc gctaaattct ggccgttttt ggcttttttg 3840
ttagacggat ccccgggtac cggtcgccac catggtgagc aagggcgagg agctgttcac 3900
cggggtggtg cccatcctgg tcgagctgga cggcgacgta aacggccaca agttcagcgt 3960
gtccggcgag ggcgagggcg atgccaccta cggcaagctg accctgaagt tcatctgcac 4020
caccggcaag ctgcccgtgc cctggcccac cctcgtgacc accctgacct acggcgtgca 4080
gtgcttcagc cgctaccccg accacatgaa gcagcacgac ttcttcaagt ccgccatgcc 4140
cgaaggctac gtccaggagc gcaccatctt cttcaaggac gacggcaact acaagacccg 4200
cgccgaggtg aagttcgagg gcgacaccct ggtgaaccgc atcgagctga agggcatcga 4260
cttcaaggag gacggcaaca tcctggggca caagctggag tacaactaca acagccacaa 4320
cgtctatatc atggccgaca agcagaagaa cggcatcaag gtgaacttca agatccgcca 4380
caacatcgag gacggcagcg tgcagctcgc cgaccactac cagcagaaca cccccatcgg 4440
cgacggcccc gtgctgctgc ccgacaacca ctacctgagc acccagtccg ccctgagcaa 4500
agaccccaac gagaagcgcg atcacatggt cctgctggag ttcgtgaccg ccgccgggat 4560
cactctcggc atggacgagc tgtacaagta aagcggccgc gactctagaa ttcgatatca 4620
agcttatcga taatcaacct ctggattaca aaatttgtga aagattgact ggtattctta 4680
actatgttgc tccttttacg ctatgtggat acgctgcttt aatgcctttg tatcatgcta 4740
ttgcttcccg tatggctttc attttctcct ccttgtataa atcctggttg ctgtctcttt 4800
atgaggagtt gtggcccgtt gtcaggcaac gtggcgtggt gtgcactgtg tttgctgacg 4860
caacccccac tggttggggc attgccacca cctgtcagct cctttccggg actttcgctt 4920
tccccctccc tattgccacg gcggaactca tcgccgcctg ccttgcccgc tgctggacag 4980
gggctcggct gttgggcact gacaattccg tggtgttgtc ggggaaatca tcgtcctttc 5040
cttggctgct cgcctgtgtt gccacctgga ttctgcgcgg gacgtccttc tgctacgtcc 5100
cttcggccct caatccagcg gaccttcctt cccgcggcct gctgccggct ctgcggcctc 5160
ttccgcgtct tcgccttcgc cctcagacga gtcggatctc cctttgggcc gcctccccgc 5220
atcgataccg tcgacctcga gacctagaaa aacatggagc aatcacaagt agcaatacag 5280
cagctaccaa tgctgattgt gcctggctag aagcacaaga ggaggaggag gtgggttttc 5340
cagtcacacc tcaggtacct ttaagaccaa tgacttacaa ggcagctgta gatcttagcc 5400
actttttaaa agaaaagggg ggactggaag ggctaattca ctcccaacga agacaagata 5460
tccttgatct gtggatctac cacacacaag gctacttccc tgattggcag aactacacac 5520
cagggccagg gatcagatat ccactgacct ttggatggtg ctacaagcta gtaccagttg 5580
agcaagagaa ggtagaagaa gccaatgaag gagagaacac ccgcttgtta caccctgtga 5640
gcctgcatgg gatggatgac ccggagagag aagtattaga gtggaggttt gacagccgcc 5700
tagcatttca tcacatggcc cgagagctgc atccggactg tactgggtct ctctggttag 5760
accagatctg agcctgggag ctctctggct aactagggaa cccactgctt aagcctcaat 5820
aaagcttgcc ttgagtgctt caagtagtgt gtgcccgtct gttgtgtgac tctggtaact 5880
agagatccct cagacccttt tagtcagtgt ggaaaatctc tagcagggcc cgtttaaacc 5940
cgctgatcag cctcgactgt gccttctagt tgccagccat ctgttgtttg cccctccccc 6000
gtgccttcct tgaccctgga aggtgccact cccactgtcc tttcctaata aaatgaggaa 6060
attgcatcgc attgtctgag taggtgtcat tctattctgg ggggtggggt ggggcaggac 6120
agcaaggggg aggattggga agacaatagc aggcatgctg gggatgcggt gggctctatg 6180
gcttctgagg cggaaagaac cagctggggc tctagggggt atccccacgc gccctgtagc 6240
ggcgcattaa gcgcggcggg tgtggtggtt acgcgcagcg tgaccgctac acttgccagc 6300
gccctagcgc ccgctccttt cgctttcttc ccttcctttc tcgccacgtt cgccggcttt 6360
ccccgtcaag ctctaaatcg ggggctccct ttagggttcc gatttagtgc tttacggcac 6420
ctcgacccca aaaaacttga ttagggtgat ggttcacgta gtgggccatc gccctgatag 6480
acggtttttc gccctttgac gttggagtcc acgttcttta atagtggact cttgttccaa 6540
actggaacaa cactcaaccc tatctcggtc tattcttttg atttataagg gattttgccg 6600
atttcggcct attggttaaa aaatgagctg atttaacaaa aatttaacgc gaattaattc 6660
tgtggaatgt gtgtcagtta gggtgtggaa agtccccagg ctccccagca ggcagaagta 6720
tgcaaagcat gcatctcaat tagtcagcaa ccaggtgtgg aaagtcccca ggctccccag 6780
caggcagaag tatgcaaagc atgcatctca attagtcagc aaccatagtc ccgcccctaa 6840
ctccgcccat cccgccccta actccgccca gttccgccca ttctccgccc catggctgac 6900
taattttttt tatttatgca gaggccgagg ccgcctctgc ctctgagcta ttccagaagt 6960
agtgaggagg cttttttgga ggcctaggct tttgcaaaaa gctcccggga gcttgtatat 7020
ccattttcgg atctgatcag cacgtgttga caattaatca tcggcatagt atatcggcat 7080
agtataatac gacaaggtga ggaactaaac catggccaag ttgaccagtg ccgttccggt 7140
gctcaccgcg cgcgacgtcg ccggagcggt cgagttctgg accgaccggc tcgggttctc 7200
ccgggacttc gtggaggacg acttcgccgg tgtggtccgg gacgacgtga ccctgttcat 7260
cagcgcggtc caggaccagg tggtgccgga caacaccctg gcctgggtgt gggtgcgcgg 7320
cctggacgag ctgtacgccg agtggtcgga ggtcgtgtcc acgaacttcc gggacgcctc 7380
cgggccggcc atgaccgaga tcggcgagca gccgtggggg cgggagttcg ccctgcgcga 7440
cccggccggc aactgcgtgc acttcgtggc cgaggagcag gactgacacg tgctacgaga 7500
tttcgattcc accgccgcct tctatgaaag gttgggcttc ggaatcgttt tccgggacgc 7560
cggctggatg atcctccagc gcggggatct catgctggag ttcttcgccc accccaactt 7620
gtttattgca gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa 7680
agcatttttt tcactgcatt ctagttgtgg tttgtccaaa ctcatcaatg tatcttatca 7740
tgtctgtata ccgtcgacct ctagctagag cttggcgtaa tcatggtcat agctgtttcc 7800
tgtgtgaaat tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaagtg 7860
taaagcctgg ggtgcctaat gagtgagcta actcacatta attgcgttgc gctcactgcc 7920
cgctttccag tcgggaaacc tgtcgtgcca gctgcattaa tgaatcggcc aacgcgcggg 7980
gagaggcggt ttgcgtattg ggcgctcttc cgcttcctcg ctcactgact cgctgcgctc 8040
ggtcgttcgg ctgcggcgag cggtatcagc tcactcaaag gcggtaatac ggttatccac 8100
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 8160
ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgcccccctg acgagcatca 8220
caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc 8280
gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata 8340
cctgtccgcc tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta 8400
tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca 8460
gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga 8520
cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg 8580
tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagaa cagtatttgg 8640
tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 8700
caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag 8760
aaaaaaagga tctcaagaag atcctttgat cttttctacg gggtctgacg ctcagtggaa 8820
cgaaaactca cgttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat 8880
ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 8940
tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc 9000
atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc 9060
tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc 9120
aataaaccag ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc 9180
catccagtct attaattgtt gccgggaagc tagagtaagt agttcgccag ttaatagttt 9240
gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc 9300
ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccca tgttgtgcaa 9360
aaaagcggtt agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt 9420
atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg 9480
cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgta tgcggcgacc 9540
gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa 9600
agtgctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt 9660
gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt 9720
caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag 9780
ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta 9840
tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat 9900
aggggttccg cgcacatttc cccgaaaagt gccacctga 9939
<210> 2
<211> 60
<212> DNA
<213> people
<400> 2
gatggcattt ggaaagcgag ctttaccacc tttaccgtga ccaaatattg gttttatcgc 60
<210> 3
<211> 192
<212> DNA
<213> synthetic
<400> 3
cgcagcgatg gcatttggaa agcgagcttt accaccttta ccgtgaccaa atattggttt 60
tatcgcgatg gcatttggaa agcgagcttt accaccttta ccgtgaccaa atattggttt 120
tatcgcgatg gcatttggaa agcgagcttt accaccttta ccgtgaccaa atattggttt 180
tatcgcggca gc 192
<210> 4
<211> 20
<212> PRT
<213> people
<400> 4
Asp Gly Ile Trp Lys Ala Ser Phe Thr Thr Phe Thr Val Thr Lys Tyr
1 5 10 15
Trp Phe Tyr Arg
20
<210> 5
<211> 64
<212> PRT
<213> synthetic
<400> 5
Arg Ser Asp Gly Ile Trp Lys Ala Ser Phe Thr Thr Phe Thr Val Thr
1 5 10 15
Lys Tyr Trp Phe Tyr Arg Asp Gly Ile Trp Lys Ala Ser Phe Thr Thr
20 25 30
Phe Thr Val Thr Lys Tyr Trp Phe Tyr Arg Asp Gly Ile Trp Lys Ala
35 40 45
Ser Phe Thr Thr Phe Thr Val Thr Lys Tyr Trp Phe Tyr Arg Gly Ser
50 55 60

Claims (5)

1. the slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal, is characterized in that: its nucleotide sequence is as described in SEQ ID NO:1.
2. according to claim 1 for suppressing the slow virus recombinant plasmid of breast tumor Epithelial and stromal conversion, it is characterized in that: the series connection of caveolin scaffolding district CAV-1 CSD expressed sequence repeats 3 times, this caveolin scaffolding district CAV-1 CSD coding nucleotide sequence as described in SEQ ID NO:3, aminoacid sequence is as described in SEQ ID NO:5, in FuGW slow virus plasmid, under ubiquitination promotor, by BamH I, be connected with Bgl II restriction enzyme site.
3. the slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal according to claim 1, is characterized in that: CAV-1 CSD coding nucleotide sequence in caveolin scaffolding district is as described in SEQ ID NO:2.
4. the slow virus recombinant plasmid transforming for suppressing breast tumor Epithelial and stromal according to claim 1, is characterized in that: CAV-1 CSD encoding amino acid sequence in caveolin scaffolding district is as described in SEQ ID NO:4.
5. as claimed in claim 1 as follows for suppressing the construction process of the slow virus recombinant plasmid that breast tumor Epithelial and stromal transforms:
(1) design of the Express Sequence Tags of caveolin scaffolding district CAV-1 CSD: from the expressed sequence in NCBI acquisition CAV-1 CSD district, by this section of sequence series connection in triplicate, at two ends, introduce BamH I and Bgl II isocaudarner restriction enzyme site, according to this section of sequences Design, be used for overlapping the primer of PCR:
primer1-5’:
CAAATATTGGTTTTATCGCGATGGCATTTGGAAAGCGAGCTTTACCACCTTTACCGTGACCAAATATTG;
primer1-3’:
GTCACGGTAAAGGTGGTAAAGCTCGCTTTCCAAATGCCATCGCGATAAAACCAATATTTGGTCACGGTA;
primer2-5’:
GGATCCCGCAGCGATGGCATTTGGAAAGCGAGCTTTACCACCTTTACCGTGACCAAATATTGGTTTTATCG;
primer2-3’: AGATCTGCTGCCGCGATAAAACCAATATTTGGTCACGGTAAAGGTGGTA;
(2) acquisition of the Express Sequence Tags of caveolin scaffolding district CAV-1 CSD: the sequence that obtains tri-series connection of CAV-1 CSD by the method for overlap joint PCR, PCR process is used TaqDNA polysaccharase, single base A is contained at these PCR product two ends, it is connected under the effect of T4 ligase enzyme in T carrier, obtain the T vector plasmid that contains tri-series connection of CAV-1 CSD;
(3) structure of recombinant plasmid FuGW-CSD: the T vector plasmid that step (two) is obtained carries out BamH I and Bgl II double digestion, BamH I and Bgl II are isocaudarners, FUGW slow virus plasmid is carried out to BamH I single endonuclease digestion, and PCR product is cloned under FUGW slow virus plasmid ubiquitination promotor by BamH I restriction enzyme site.
CN201310494959.0A 2013-10-22 2013-10-22 A kind of slow virus recombinant plasmid for suppressing breast tumor Epithelial and stromal to transform Expired - Fee Related CN103540612B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310494959.0A CN103540612B (en) 2013-10-22 2013-10-22 A kind of slow virus recombinant plasmid for suppressing breast tumor Epithelial and stromal to transform

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310494959.0A CN103540612B (en) 2013-10-22 2013-10-22 A kind of slow virus recombinant plasmid for suppressing breast tumor Epithelial and stromal to transform

Publications (2)

Publication Number Publication Date
CN103540612A true CN103540612A (en) 2014-01-29
CN103540612B CN103540612B (en) 2016-03-30

Family

ID=49964465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310494959.0A Expired - Fee Related CN103540612B (en) 2013-10-22 2013-10-22 A kind of slow virus recombinant plasmid for suppressing breast tumor Epithelial and stromal to transform

Country Status (1)

Country Link
CN (1) CN103540612B (en)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
刘小旭等: "乳腺癌组织小窝蛋白-1的表达", 《第四军军医大学学报》, vol. 29, no. 20, 31 October 2008 (2008-10-31), pages 1885 - 1887 *
吕学军: "Caveolin-1在LPS诱导AT-1细胞和小鼠肺部急性损伤中的作用及机制研究", 《中国博士学位论文全文数据库医药卫生科技辑》, no. 12, 15 December 2010 (2010-12-15) *
林世荣等: "慢病毒载体介导人缝隙连接蛋白43基因在大鼠骨髓间充质干细胞中的表达", 《中国动脉硬化杂志》, vol. 16, no. 2, 29 February 2008 (2008-02-29), pages 107 - 110 *
王洪权等: "TAT-BACEsp-GFP三融合基因慢病毒载体的构建与鉴定", 《西安交通大学学报(医学版)》, vol. 29, no. 1, 29 February 2008 (2008-02-29), pages 7 - 10 *
王露露等: "慢病毒介导HLA-G转基因小鼠的建立", 《第三军医大学学报》, vol. 34, no. 14, 30 July 2012 (2012-07-30), pages 1392 - 1396 *

Also Published As

Publication number Publication date
CN103540612B (en) 2016-03-30

Similar Documents

Publication Publication Date Title
CN101550406A (en) Method for preparing multipotential stem cells, reagent kit and application
US6303336B1 (en) Herpes virus entry receptor protein
CN110945127B (en) Viral vectors encoding recombinant FIX with increased expression for gene therapy of hemophilia B
CN110592108B (en) Infectious recombinant cloning method for II-type VII-type epidemic NDV strain DHN3
CN106591371A (en) CD16A/GPC3 double-antibody lentivirus expression vector, and construction method and application thereof
CN112481271B (en) Transcription factor C/EBPZ for regulating and controlling formation of adipocytes and application thereof
CN108103088B (en) Optimized gene of recombinant GLP-1 analogue Fc fusion protein and application thereof
CN101250548B (en) Shuttle plasmid and derivative plasmid thereof
CN114150001A (en) Construction method of CRISPR/Cas9 vector for toxoplasma gondii gene editing
CN113025752B (en) Internal reference gene, kit and detection method for PCR detection of 2019-nCoV and SARS virus
KR20140122729A (en) Use of lysozyme as a tag
CN107699535A (en) A kind of recombined bacillus subtilis for inducing synthesis guanosine diphosphate fucose and its construction method and application
CN113943737A (en) Application of chicken CTGF gene in inhibiting differentiation of chicken preadipocytes
CN103540612A (en) Slow virus recombinant plasmid for inhibiting epithelial-mesenchymal transition of breast tumor
CN112342245B (en) CRISPR-Cas13d system for promoting suspension of CHO cells and recombinant CHO cells
US20210386870A1 (en) Fibroblast growth factor 21 (FGF21) gene therapy
KR102009270B1 (en) Recombinant foot-and-mouth disease virus expressing protective antigen of type O-Thi60
CN107474131A (en) One kind restructuring bovine serum albumin mature peptide and its preparation method and application
CN110564766A (en) Preparation method of whole genome expression vector pBR322-DHN3
CN106978432B (en) Knock out carrier construction method and the application of chlamydomonas endogenous gene and expression alien gene
CN109321602B (en) PKD2 recombinant overexpression vector and construction method and application thereof
CN111961651A (en) Gene recombinant PD-1 antibody autocrine human gamma T cell and construction method and application thereof
CN111663187A (en) Staphylococcus aureus transposon sequencing library and construction method
CN111909957B (en) Genetic transformation method of haematococcus pluvialis
CN113481328B (en) Kit for detecting GI.5 norovirus in clinical samples and special primer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160330

Termination date: 20171022